Clin2Atlas
AtlasMetabolic, hormones & kidneysChronic kidney disease

Chronic kidney disease due to glomerulonephritis

2Disease-modifyingAI-generated

Glomerulonephritis-related CKD: treatable, not curable, progression can slow.AI-generated

Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251989 — Epoetin alfa approved (FDA)1993 — Pantothenic acid approved (FDA)1993 — Riboflavin approved (FDA)1994 — Budesonide approved (FDA)1995 — Losartan approved (FDA)1997 — Irbesartan approved (FDA)1997 — Epoetin beta approved (FDA)1998 — Sevelamer hydrochloride approved (FDA)1998 — Paricalcitol approved (FDA)1999 — Doxercalciferol approved (FDA)1999 — Oseltamivir approved (FDA)2000 — Iron sucrose approved (FDA)2001 — Darbepoetin alfa approved (FDA)2002 — Epoetin delta approved (FDA)2004 — Cinacalcet approved (FDA)2004 — Lanthanum carbonate approved (FDA)2007 — Sevelamer approved (FDA)2007 — Methoxy polyethylene glycol-epoetin beta approved (FDA)2007 — Epoetin zeta approved (FDA)2009 — Epoetin theta approved (FDA)2009 — Ferumoxytol approved (FDA)2010 — Ceftaroline fosamil approved (FDA)2011 — Belimumab approved (FDA)2012 — Dapagliflozin approved (FDA)2014 — Empagliflozin approved (FDA)2015 — Ferric pyrophosphate citrate approved (FDA)2016 — Etelcalcetide approved (FDA)2019 — Sotagliflozin approved (FDA)2021 — Finerenone approved (FDA)2021 — Difelikefalin approved (FDA)2021 — Voclosporin approved (FDA)2021 — Roxadustat approved (FDA)2023 — Iptacopan approved (FDA)2023 — Vadadustat approved (FDA)2023 — Daprodustat approved (FDA)2023 — Sparsentan approved (FDA)
1989: Drug approval — Epoetin alfa approved (FDA). 1993: Drug approval — Pantothenic acid approved (FDA). 1993: Drug approval — Riboflavin approved (FDA). 1994: Drug approval — Budesonide approved (FDA). 1995: Drug approval — Losartan approved (FDA). 1997: Drug approval — Irbesartan approved (FDA). 1997: Drug approval — Epoetin beta approved (FDA). 1998: Drug approval — Sevelamer hydrochloride approved (FDA). 1998: Drug approval — Paricalcitol approved (FDA). 1999: Drug approval — Doxercalciferol approved (FDA). 1999: Drug approval — Oseltamivir approved (FDA). 2000: Drug approval — Iron sucrose approved (FDA). 2001: Drug approval — Darbepoetin alfa approved (FDA). 2002: Drug approval — Epoetin delta approved (FDA). 2004: Drug approval — Cinacalcet approved (FDA). 2004: Drug approval — Lanthanum carbonate approved (FDA). 2007: Drug approval — Sevelamer approved (FDA). 2007: Drug approval — Methoxy polyethylene glycol-epoetin beta approved (FDA). 2007: Drug approval — Epoetin zeta approved (FDA). 2009: Drug approval — Epoetin theta approved (FDA). 2009: Drug approval — Ferumoxytol approved (FDA). 2010: Drug approval — Ceftaroline fosamil approved (FDA). 2011: Drug approval — Belimumab approved (FDA). 2012: Drug approval — Dapagliflozin approved (FDA). 2014: Drug approval — Empagliflozin approved (FDA). 2015: Drug approval — Ferric pyrophosphate citrate approved (FDA). 2016: Drug approval — Etelcalcetide approved (FDA). 2019: Drug approval — Sotagliflozin approved (FDA). 2021: Drug approval — Finerenone approved (FDA). 2021: Drug approval — Difelikefalin approved (FDA). 2021: Drug approval — Voclosporin approved (FDA). 2021: Drug approval — Roxadustat approved (FDA). 2023: Drug approval — Iptacopan approved (FDA). 2023: Drug approval — Vadadustat approved (FDA). 2023: Drug approval — Daprodustat approved (FDA). 2023: Drug approval — Sparsentan approved (FDA)

What's being tested now

2001: 2 trials started2003: 2 trials started2004: 1 trials started2006: 3 trials started2008: 4 trials started2009: 2 trials started2010: 5 trials started2011: 4 trials started2012: 2 trials started2013: 6 trials started2014: 3 trials started2015: 3 trials started2016: 9 trials started2017: 7 trials started2018: 14 trials started2019: 26 trials started2020: 25 trials started2021: 40 trials started2022: 77 trials started2023: 98 trials started2024: 212 trials started2025: 301 trials started2026: 324 trials started201020202026324

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 1099 active Chronic kidney disease trials on Clin2 →

Where we are

AI-generated

Chronic kidney disease due to glomerulonephritis is at the disease-modifying stage: no cure exists once CKD is established, but ACE inhibitors/ARBs and immunosuppression for active inflammatory subtypes can slow decline and reduce events. Some early or specific forms are reversible. Over decades, outlook has improved gradually; progression is often slower with modern therapy, though many still advance to kidney failure. A key milestone was FDA approval of chlorothiazide in 1958, which made blood-pressure control more practical. The pipeline is active: 1,063 trials started in the last five years, including 91 phase-3 studies, with 1,099 currently active.

Can chronic kidney disease from glomerulonephritis be reversed?
Once CKD is established, damage is generally irreversible. Some early or specific inflammatory forms may improve with immunosuppression. Treatment focuses on slowing further decline and managing complications.
How does this condition usually progress over time?
Progression varies. Without treatment, kidney function often declines steadily over years. With blood-pressure control and appropriately used immunosuppression, the decline can slow, but many people eventually reach advanced kidney failure.
What treatments have changed the outlook?
The 1958 approval of chlorothiazide was a turning point, making blood-pressure control easier and slowing kidney damage. Later ACE inhibitors, ARBs, and immunosuppressives improved kidney survival. Ongoing trials continue testing new approaches.
Are there new treatments being studied?
Yes. More than 1,063 trials have started in the last five years, including 91 phase-3 studies, and 1,099 are currently active. Research focuses on slowing progression and better targeting inflammation.

Related

Chronic kidney disease due to diabetes mellitus type 1Chronic kidney disease due to diabetes mellitus type 2Chronic kidney disease due to hypertensionChronic kidney disease due to other and unspecified causes

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.